Tianbo Xu1, Hailong Ruan2, Zhengshuai Song3, Qi Cao4, Keshan Wang5, Lin Bao6, Di Liu7, Junwei Tong8, Hongmei Yang9, Ke Chen10, Xiaoping Zhang11. 1. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: tianboxu@hust.edu.cn. 2. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: 827845598@qq.com. 3. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: 867703966@qq.com. 4. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: 878635789@qq.com. 5. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: wks4869@hust.edu.cn. 6. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: 2417221775@qq.com. 7. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: 289739897@qq.com. 8. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: 1316717458@qq.com. 9. Department of Pathogenic Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: macy.yang66@gmail.com. 10. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: shenke@hust.edu.cn. 11. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: xzhang@hust.edu.cn.
Abstract
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies in urinary system. However, there are still no reliable biomarkers for the diagnosis and prognosis of ccRCC. In this study, we aimed to screen candidate biomarkers and potential therapeutic targets for ccRCC. METHODS: Differentially expressed genes (DEGs) were screened using NetworkAnalyst. Protein-protein interaction (PPI) network and weighted gene co-expression network analysis (WGCNA) were utilized to identify hub genes. Then, we assessed the prognostic and diagnostic values of hub genes to screen candidate biomarkers. Gene Set Enrichment Analysis (GSEA) was applied to reveal potential mechanisms of candidate biomarkers in ccRCC. Oncomine database and The Human Protein Atlas were used to verify the expression of candidate biomarkers online. In addition, qRT-PCR, Enzyme linked immunosorbent assay (ELISA) and Immunohistochemistry (IHC) assays were performed to validate the expression level of candidate biomarkers in ccRCC cells and tissues. RESULTS: A total of 771 genes were identified as DEGs. GO function analysis showed that DEGs were mostly enriched in excretion, apical part of cell and monovalent inorganic cation transmembrane transporter activity. KEGG pathway analysis demonstrated that DEGs were mostly involved in Neuroactive ligand-receptor interaction. After utilizing PPI network and WGCNA, nine genes (IFNG, CXCR3, PMCH, CD2, FASLG, CXCL13, CD8A, CD3D and GZMA) were identified as the hub genes. Moreover, survival analysis exhibited that high expression of CXCL13 predicted poor survival in both overall survival (OS) and disease free survival (DFS). The ROC curves indicated that CXCL13 could distinguish ccRCC samples from normal kidney samples. High expression of CXCL13 group was mostly associated with RB and MEL18 pathways by GSEA. Furthermore, qRT-PCR, ELISA and IHC results showed that the expression of CXCL13 was elevated in ccRCC. CONCLUSIONS: Our study illustrated that CXCL13 had good diagnostic and prognostic value, which may become a candidate biomarker and therapeutic target for ccRCC.
BACKGROUND:Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies in urinary system. However, there are still no reliable biomarkers for the diagnosis and prognosis of ccRCC. In this study, we aimed to screen candidate biomarkers and potential therapeutic targets for ccRCC. METHODS: Differentially expressed genes (DEGs) were screened using NetworkAnalyst. Protein-protein interaction (PPI) network and weighted gene co-expression network analysis (WGCNA) were utilized to identify hub genes. Then, we assessed the prognostic and diagnostic values of hub genes to screen candidate biomarkers. Gene Set Enrichment Analysis (GSEA) was applied to reveal potential mechanisms of candidate biomarkers in ccRCC. Oncomine database and The Human Protein Atlas were used to verify the expression of candidate biomarkers online. In addition, qRT-PCR, Enzyme linked immunosorbent assay (ELISA) and Immunohistochemistry (IHC) assays were performed to validate the expression level of candidate biomarkers in ccRCC cells and tissues. RESULTS: A total of 771 genes were identified as DEGs. GO function analysis showed that DEGs were mostly enriched in excretion, apical part of cell and monovalent inorganic cation transmembrane transporter activity. KEGG pathway analysis demonstrated that DEGs were mostly involved in Neuroactive ligand-receptor interaction. After utilizing PPI network and WGCNA, nine genes (IFNG, CXCR3, PMCH, CD2, FASLG, CXCL13, CD8A, CD3D and GZMA) were identified as the hub genes. Moreover, survival analysis exhibited that high expression of CXCL13 predicted poor survival in both overall survival (OS) and disease free survival (DFS). The ROC curves indicated that CXCL13 could distinguish ccRCC samples from normal kidney samples. High expression of CXCL13 group was mostly associated with RB and MEL18 pathways by GSEA. Furthermore, qRT-PCR, ELISA and IHC results showed that the expression of CXCL13 was elevated in ccRCC. CONCLUSIONS: Our study illustrated that CXCL13 had good diagnostic and prognostic value, which may become a candidate biomarker and therapeutic target for ccRCC.